OASMIA: EMEA FINAL ADVICE FOR START OF OASMIA´S PACLICAL® PHASE III PROGRAM

(NGM: OASM A)

Oasmia has received a final advice from the EMEA on the clinical Phase III
program for Paclical®. The program is scheduled to begin immediately. 

The Phase III development program for Paclical® on the indication ovarian
cancer has received a final advice from the European Medicines Agency (EMEA).
Oasmia is now ready for the next step in the development process. The company
has previously received an Orphan Drug designation on ovarian cancer. The
designation protects the product from direct competition for ten years on the
indication when registered. 

Oasmia has designed the program with assistance from the EMEA to make the
future registration process as efficient as possible. The company now plans to
initiate the Phase III-program immediately. The Program will be carried out at
35 different sites in Europe. 

- This is a major milestone for the company's clinical program and is a very
important step in the development of Paclical® for all indications and not just
ovarian cancer, says Oasmia CEO Julian Aleksov in a quick comment. 

The positive response will also significantly benefit the development of the
company's other products as confidence in the Oasmia oncology portfolio
continues to grow. 




More information is available at www.ngm.se or www.oasmia.com
Media contact: Maria Lundén +46 (0) 18 50 54 40 e-mail: info@oasmia.com 

Oasmia Pharmaceutical is a pharmaceutical company that specialises in the
treatment of severe diseases. 
A pharmaceutical company based on the latest concepts in bio-organic chemistry.
The main idea is to improve the treatment of serious diseases. Primarily, this
development is in oncology but Oasmia also in antibiotics, asthma and
neurological diseases. Oasmia has in-house production capacity of
pharmaceuticals for clinical trials, both company related and others. Oasmia
has developed several products based on existing pharmaceuticals in a new
environment leading to new solutions for cancer treatment. These products give
Oasmia a solid product portfolio within oncology with several products in
clinical or pre-clinical phase. Oasmia is listed on NGM Eguity.